Sectra to acquire Oxipit
Sectra is finalizing a deal to acquire Oxipit, a company that specializes in developing artificial intelligence (AI) solutions targeted at medical imaging.
Oxipit developed ChestLink, which holds the first CE Class 2B certification for autonomous AI in chest X-ray analysis. ChestLink is a tool that autonomously analyzes chest radiographs and removes high-confidence normal exams from radiologist worklists, allowing them to focus their attention on more urgent cases. The tool’s CE certification status requires its performance to be continuously validated to ensure it meets the highest safety thresholds.
President and CEO of Sectra, Torbjörn Kronander, believes incorporating the AI-powered tool into Sectra’s suite of solutions will offer its clients numerous benefits beyond workflow alone.
“The ability to autonomously clear high-confidence normal cases mark a transformative step for radiology. By combining clinical confidence with intelligent automation, we can expand capacity, reduce radiologist workload, and generate substantial financial benefits through higher productivity and lower cost,” Kronander said in a statement. “We look forward to continuing to sell Oxipit products in Europe and advancing the necessary regulatory approvals to bring it to more markets worldwide.”
“This is an important step in Oxipit’s journey,” added Peter Corscadden, CEO of Oxipit. “Sectra’s global footprint, strong clinical partnerships, and deep integration into radiology workflows create a powerful platform to responsibly scale autonomous AI. Together, we can accelerate access to AI solutions that fit naturally into daily reporting practice.”
The new agreement stipulates that Oxipit’s team will work within Sectra’s Imaging IT Solutions as a dedicated AI development center. The company is already working to develop CT and musculoskeletal solutions, but ChestLink is currently available via Sectra Amplifier Marketplace for AI.
Full financials for the agreement have not yet been disclosed, but Sectra is set to finance the deal with its own funds, putting down cash up front. The deal is accompanied by additional contingencies based on commercial and regulatory milestones. It is expected to be finalized in the weeks ahead as customary closing conditions are met.
Learn more here.
In addition to her background in journalism, Hannah also has patient-facing experience in clinical settings, having spent more than 12 years working as a registered rad tech. She began covering the medical imaging industry for Innovate Healthcare in 2021.